VITRAKVI

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Turkey, UK.

Active ingredients

The drug VITRAKVI contains one active pharmaceutical ingredient (API):

1	Larotrectinib UNII PF9462I9HX - LAROTRECTINIB
	Larotrectinib is an adenosine triphosphate (ATP)-competitive and selective tropomyosin receptor kinase (TRK) inhibitor. The TRK family of proteins, TRKA, TRKB, and TRKC, is encoded by NTRK1, NTRK2 and NTRK3 genes. Larotrectinib was rationally designed to avoid activity with off-target kinases. It is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
	Read more about Larotrectinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VITRAKVI Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)
VITRAKVI Oral solution	MPI, EU: SmPC	European Medicines Agency (EU)
VITRAKVI Capsule / Oral solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX12		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	538920030030007, 538920030030107, 538920040030407
CA	Health Products and Food Branch	02490315, 02490323, 02490331
EE	Ravimiamet	1801145, 1801156, 1801167
FI	Lääkealan turvallisuus- ja kehittämiskeskus	167776, 429452, 499084
FR	Base de données publique des médicaments	64373909, 65942815, 67022406
GB	Medicines & Healthcare Products Regulatory Agency	377474, 392356, 392359
HK	Department of Health Drug Office	66491, 66492, 66493
IL	מִשְׂרַד הַבְּרִיאוּת	8549, 8737
IT	Agenzia del Farmaco	048215014, 048215026, 048215038, 048215040
JP	医薬品医療機器総合機構	4291071M1029, 4291071M2025, 4291071S1028
LT	Valstybinė vaistų kontrolės tarnyba	1088495, 1088496, 1088497, 1092623
NL	Z-Index G-Standaard, PRK	206156, 206164, 206172
PL	Rejestru Produktów Leczniczych	100426670, 100426718, 100426760
TR	İlaç ve Tıbbi Cihaz Kurumu	8699546156382, 8699546156399, 8699546650040
US	FDA, National Drug Code	50419-390, 50419-391, 50419-392, 71777-390, 71777-391, 71777-392